WO 2003 077914: Binimetinib Patent Information
The patent application WO 2003 077914, filed on March 7, 2003, relates to binimetinib, a MEK inhibitor. This application is part of the patent landscape surrounding the drug, which is used in combination therapy for certain types of cancer [1].
What is Binimetinib Used For?
Binimetinib, also known as MEK162 or ARRY-162, is a potent and selective inhibitor of MEK1 and MEK2 enzymes [1]. These enzymes are part of the RAS/RAF/MEK/ERK signaling pathway, which is often dysregulated in various cancers and can promote tumor cell growth and survival. Binimetinib is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib [2][3].
When Does the Patent for Binimetinib Expire?
Patent expiration dates for drugs can be complex due to multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and method of use. Specific patent expiration timelines for binimetinib would need to be analyzed through detailed patent searches. DrugPatentWatch.com is a resource that tracks patent expirations for pharmaceuticals, which can provide more precise information on when market exclusivity for binimetinib may end [4].
Who Developed Binimetinib?
Binimetinib was originally developed by Array BioPharma, which was later acquired by Pfizer Inc. in 2019 [2][5].
What is the Mechanism of Action for Binimetinib?
Binimetinib functions by inhibiting the activity of MEK1 and MEK2 kinases [1]. These kinases are critical components of the mitogen-activated protein kinase (MAPK) pathway, also known as the RAS/RAF/MEK/ERK pathway. By blocking MEK, binimetinib prevents the phosphorylation and activation of downstream ERK proteins, thereby suppressing abnormal cell proliferation and survival driven by mutations in this pathway, such as BRAF mutations [1][3].
What are the Risks Associated with Binimetinib Treatment?
Common side effects reported with binimetinib, particularly when used in combination with encorafenib, include fatigue, nausea, diarrhea, vomiting, abdominal pain, and dry skin [2]. More serious risks can include cardiac issues such as decreased ejection fraction, ocular toxicity (retinal vein occlusion, retinal pigment epithelial detachment), and skin toxicities [2][3].
Are There Other Drugs Similar to Binimetinib?
Binimetinib belongs to a class of drugs known as MEK inhibitors. Other MEK inhibitors available or in development include trametinib and cobimetinib, which are also used in targeted cancer therapy, often in combination with BRAF inhibitors [6].
What is the Regulatory Status of Binimetinib?
Binimetinib has received regulatory approval in major markets like the United States and Europe for specific indications, primarily in combination with encorafenib for BRAF-mutated melanoma. Its approval is contingent on meeting rigorous safety and efficacy standards set by regulatory bodies such as the FDA and EMA [2][3].
How Does Binimetinib Compare to Other Cancer Therapies?
Binimetinib's efficacy is demonstrated in clinical trials, particularly when used in combination with encorafenib, showing improved progression-free survival and overall survival compared to older chemotherapy regimens for BRAF-mutated melanoma [3]. Its targeted mechanism of action aims to provide more specific anti-cancer effects with potentially fewer systemic side effects than traditional chemotherapy, though specific side effect profiles differ [2][3].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/
[3] https://www.ema.europa.eu/
[4] https://drugpatentwatch.com/
[5] https://www.pfizer.com/
[6] https://www.ncbi.nlm.nih.gov/